N1087
An undisclosed Eurofarma candidate at phase 3 in female pattern hair loss.
- Developed by
- Eurofarma Laboratórios
- Current phase
- Phase 3
- Indications
- Female pattern hair loss
- Last public activity
- January 2026
- Record confidence
- Low
Large confirmatory trials. The last step before filing.
Why it matters
Female pattern hair loss is chronically under-served by the pipeline, so a registrational trial aimed specifically at it is worth recording even when the composition is not disclosed. Brazil runs a substantial share of the world's hair-loss trials and almost none of it reaches English-language coverage.
Development history
No phase changes recorded yet.
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Participants With Female Pattern Hair Loss (MINORA-WOMEN)
Eurofarma Laboratorios S.A. · n=372 · January 2027
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- N1087 in female pattern hair loss — ClinicalTrials.gov